Halozyme Therapeutics

Halozyme is a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. Its lead proprietary program, the investigational drug PEGPH20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. By breaking down potential barriers to cancer, PEGPH20 may help make existing treatments more effective allowing therapies to reach the tumor. 
In addition to the Company's proprietary product portfolio, Halozyme has value-driving partnerships with leading pharmaceutical companies including Roche, Pfizer, Janssen, Baxalta, AbbVie and Lilly for its ENHANZE drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. This technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. 

Company Growth (employees)
Type
Public
HQ
San Diego, US
Founded
1998
Size (employees)
259 (est)+20%
Halozyme Therapeutics was founded in 1998 and is headquartered in San Diego, US

Halozyme Therapeutics Office Locations

Halozyme Therapeutics has an office in San Diego
San Diego, US (HQ)
11388 Sorrento Valley Road

Halozyme Therapeutics Data and Metrics

Halozyme Therapeutics Financial Metrics

Halozyme Therapeutics's revenue was reported to be $146.7 m in FY, 2016 which is a 9% increase from the previous period.
USD

Revenue (FY, 2016)

146.7 m

Revenue growth (FY, 2015 - FY, 2016), %

9%

Gross profit (FY, 2016)

113.5 m

Gross profit margin (FY, 2016), %

77%

Net income (FY, 2016)

(103 m)

EBIT (FY, 2016)

(83.2 m)

Market capitalization (12-Jul-2017)

1.7 b

Closing share price (12-Jul-2017)

13

Cash (31-Dec-2016)

66.8 m
Halozyme Therapeutics's current market capitalization is $1.7 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

54.8 m75.3 m135.1 m146.7 m

Revenue growth, %

37%79%9%

Cost of goods sold

6.2 m22.7 m29.2 m33.2 m

Gross profit

48.6 m52.6 m105.8 m113.5 m

Gross profit Margin, %

89%70%78%77%

R&D expense

150.8 m

General and administrative expense

45.9 m

Operating expense total

129 m115.6 m133.3 m229.9 m

EBIT

(80.4 m)(63 m)(27.5 m)(83.2 m)

EBIT margin, %

(147%)(84%)(20%)(57%)

Interest expense

3.3 m5.6 m5.2 m20 m

Pre tax profit

(101.9 m)

Income tax expense

1.2 m

Net Income

(83.5 m)(68.4 m)(32.2 m)(103 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

27.4 m61.4 m43.3 m66.8 m

Accounts Receivable

9.1 m9.1 m32.4 m15.7 m

Inventories

6.2 m6.4 m9.5 m14.6 m

Current Assets

95.2 m161.3 m171.8 m256.5 m

PP&E

3.4 m3 m3.9 m4.3 m

Total Assets

101.8 m166 m181.8 m261.5 m

Accounts Payable

3.1 m3 m4.5 m3.6 m

Current Liabilities

25.5 m24.3 m62.5 m54.6 m

Additional Paid-in Capital

361.9 m491.7 m525.6 m552.7 m

Retained Earnings

(382.1 m)(450.4 m)(482.7 m)(585.3 m)

Total Equity

41.4 m43 m

Financial Leverage

4 x4.2 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(83.5 m)(68.4 m)(32.2 m)(103 m)

Depreciation and Amortization

1.2 m1.8 m1.7 m2.4 m

Accounts Receivable

6.6 m(52 k)(23 m)16.7 m

Inventories

(3.5 m)(236 k)(3.1 m)(5.1 m)

Accounts Payable

7.9 m(816 k)13.9 m(244 k)

Cash From Operating Activities

(49.3 m)(47.5 m)(37.1 m)(50.4 m)

Purchases of PP&E

(2.3 m)(1.4 m)(2.4 m)(3.1 m)

Cash From Investing Activities

(47.9 m)(33 m)5.9 m(76.8 m)

Long-term Borrowings

(54.3 m)

Cash From Financing Activities

25.1 m114.5 m13.1 m150.6 m

Interest Paid

3.1 m3.5 m3.8 m3.9 m

Income Taxes Paid

1.4 m
USDY, 2016

Revenue/Employee

679.1 k

Halozyme Therapeutics Market Value History

Halozyme Therapeutics Online and Social Media Presence

Halozyme Therapeutics Company Life and Culture

You may also be interested in